\
&
Contact us
\
&
Contact us
This was 4 years ago
Locationonline
ProgrammesBridge2Horizon, the network of national contact points (NCPs) supporting the transition to the world's largest research & Innovation programme, Horizon Europe, is organising an online Face2Face brokerage event on 2-3 December to accompany the launch of Horizon Europe’s second year of calls, and the launch of calls Technology and Experimentation Facilities (TEF) in Artificial Intelligence in multiple sectors under the Digital Europe (DIGITAL) programme. Calls for the sectoral TEFs under DIGITAL are expected to open in the 2nd half of February 2022.
The brokerage event is supported by the networks of NCPs for Digital and Industry. Face2Face brokerage events traditionally attract over 1000 academics, researchers, industrial stakeholders, SMEs and public sector actors from across Europe and beyond. The matchmaking event offers a unique opportunity to meet your ideal collaborators for upcoming calls. Furthermore, the marketplace, will feature top digital experts to complement consortia in other areas of high relevance to achieve Europe’s green & digital transformation.
More information and registration on https://digital-industry-2021.b2match.io/
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
